Welcome to AATOD’s updated and improved website, which incorporates a number of new sections, focusing on our long running Opioid Use Study, our work with Hepatitis C, criminal justice initiatives, and our conference planning initiatives.
We have recently released our conference registration materials in anticipation of the Baltimore conference, which will convene at the Marriott Waterfront Hotel between October 29 – November 2, 2016. Vickie Walters, Conference Chair, is already doing a great job of organizing all of our planning partners and we anticipate another extremely informative conference for our field.
We have just completed three major policy papers for the Substance Abuse and Mental Health Services Administration (SAMHSA), providing opportunities to further integrate the services of OTP Hub sites with other behavioral and primary care providers, DATA 2000 practices, drug courts, correctional facilities, and child protective services. One of the White Papers also focuses on the use of Health Homes with OTPs based on models in Rhode Island and Maryland, in addition to a comprehensive overview of the successful Hub & Spoke model in Vermont.
We plan on tackling the problem of Medicaid reimbursement for OTP services, focusing on the 17 states that do not provide any such reimbursement at the present time. We will work with a number of policy partners, including the Legal Action Center and NASADAD in addition to the federal agencies under the jurisdiction of the Department of Health and Human Services. We realize that this will be a challenge but we also recognize that we have the benefit of an incredible alignment between the White House Office of National Drug Control Policy and DHHS. We plan on developing webinars to move this policy along, starting in the first quarter of 2016.
We know that 2016 will be another year of incredible, active policy in support of expanding access to treatment for opioid addiction services. AATOD will continue to drive home the point that when such service delivery is expanded, it is consistent with evidence based practices in support of the three federally approved medications to treat opioid addiction and based on what we have learned from countless research studies over the course of the past 50 years.
Thank you for your interest in our work!
Mark W. Parrino, M.P.A.